Revolution Medicines posts investor presentation on RASONQUE FDA approval

PUBT · 2d ago
Revolution Medicines posts investor presentation on RASONQUE FDA approval
  • Revolution Medicines released an investor presentation covering U.S. FDA approval of RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma.
  • Label: adults with metastatic PDAC with at least one prior systemic therapy, or not candidates for multiagent systemic therapy.
  • Phase 3 RASolute 302: median overall survival 13.2 months vs 6.7 months; hazard ratio 0.40.
  • Median progression-free survival 7.2 months vs 3.6 months; hazard ratio 0.49.
  • Recommended dose 300 mg once daily; serious adverse reactions in 30% of patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein.